drugset / Trial / NCT00263055

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

NCT00263055

Phase 4 Completed Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Safety \& tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian patients

Timeline

Start
2004-08
Primary completion
2005-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule

Indications